OncLive - Bringing the Oncology Community Together

May 2012: Trials in Progress

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Oncology & Biotech News > Trials in Progress

All Patients With Colorectal Cancer Should Be Genetically Screened

Universal tumor testing and a detailed personal and family history assessment are recommended for all patients with newly diagnosed colorectal cancer.

Conferences > 2012 Oncology Nursing Society Congress

Brivanib Plus Cetuximab Delivers Mixed Results in Colorectal Study

Adding brivanib alaninate to cetuximab had no survival advantage over cetuximab alone in patients with KRAS wild-type chemorefractory metastatic colorectal cancer.

Oncology Live > Clinical Insights

Research Backs Anti-EGFR Therapy in mCRC With Wild-Type KRAS

New research on predictive and prognostic biomarkers for therapy targeting EGFR strongly suggests that panitumumab should be reserved for mCRC tumors with wild-type KRAS.

Oncology Live > Clinical Insights

Addition of Oxaliplatin to Adjuvant Therapy for Late-Stage Colon Cancer Shows Benefit in Real-World Setting

Adding oxaliplatin to conventional chemotherapy increases survival in patients with advanced colon cancer in a broad range of community practice settings.

Oncology & Biotech News > Clinical Trial Reports

Optical Biomarkers Distinguish Risk Levels in Barrett's Esophagus

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Oncology Live > Clinical Insights

Many Patients Continue to Smoke After Cancer Diagnosis

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

Oncology & Biotech News > Clinical Trial Reports

Prognostic Factors for Progression of Neuroendocrine Tumors Identified in Reanalysis of RADIANT-2

The addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progression-free survival in patients with advanced neuroendocrine tumors.

Oncology & Biotech News > Conference Highlights

Adjuvant Cetuximab Fails to Improve Survival in Colon Cancer

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

> Web Exclusives

Serum-Based Protein Immunoassay Can Detect Early Pancreatic Cancer

An immunoassay to detect the presence of PAM4 showed promise for the detection and diagnosis of early-stage pancreatic ductal adenocarcinoma.

Oncology & Biotech News > Conference Highlights

More Research Needed to Define Appropriate Targets for Biologic Therapy of Gastric Cancer

More research is needed to define molecular subtypes of gastric cancer and identify appropriate targets for clinical use.

Oncology & Biotech News > Conference Highlights

Regorafenib Potential Treatment for Metastatic Colorectal Cancer Failing Standard Treatment Options

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

Oncology & Biotech News > Conference Highlights

Prediagnostic Obesity Curbs Colorectal Cancer Survival

Patients who are obese before being diagnosed with colorectal cancer are more likely to die of their disease than patients who are at a normal weight prediagnosis.

Oncology & Biotech News > Clinical Trial Reports

Everolimus Plus Octreotide LAR Is Effective in Advanced Neuroendocrine Tumors

Combination therapy with everolimus and the octreotide LAR increases the median PFS in patients with advanced neuroendocrine tumors associated with carcinoid syndrome.

Oncology & Biotech News > Clinical Trial Reports

Baseline Glucose Levels in Older Women May Be Linked to Colorectal Cancer Risk

New findings suggest that increased serum glucose levels may be a risk factor for colorectal cancer in postmenopausal women.

Oncology & Biotech News > Clinical Trial Reports

Expanded Use of Gleevec Approved in Patients With GIST

The FDA granted regular approval for imatinib for treating patients after the surgical removal of KIT-positive GISTs.

> Web Exclusives

Lower Rate of Colorectal Cancer Screening May Be Linked to Higher Cancer Fatalism

Higher cancer fatalism, a term that refers to the belief that a cancer diagnosis leads inevitably to death, may be associated with a lower rate of colorectal cancer screening.

Oncology & Biotech News > Clinical Trial Reports

Men With Colorectal Cancer Often Not Consulted About Risks for Erectile Dysfunction

Men with colorectal cancer are not routinely informed about the potential for erectile dysfunction or how the condition can best be managed.

Oncology & Biotech News > Clinical Trial Reports

Prediagnosis Primary Care Visits Improve Outcomes in Medicare Patients With Colorectal Cancer

Medicare beneficiaries with CRC who made a higher number of visits to their PCP before their diagnosis had lower disease-related mortality and lower all-cause mortality.

Oncology & Biotech News > Clinical Trial Reports

Colorectal Tumor Marker: Molecular Evaluation Sheds Light on Negative Lymph Node Status

The presence or absence of lymph node involvement has long been recognized as a critically relevant prognostic factor in solid tumor oncology.

Oncology Live > From the Editor